Animal model |
Species |
Clinically Relevant Positive Control and MOA of Test Compounds Tested |
Disease Target |
Therapeutic Indication |
Publication |
---|
Ovalbumin sensitisation and challenge model (airway challenge) |
Brown Norway Rat, mouse, guinea pig |
Steroids (systemic and inhaled), dexamethasone, budesonide, fluticasone propionate, PI3Kinase |
Multiple anti-inflammatory targets |
Asthma |
Alterations in airway mechanics, inflammatory biomarkers and lung histopathology in a rat model of allergen –induced airway inflammation |
Ovalbumin sensitisation and challenge model (nasal upper airway challenge) |
Mouse |
Steroid ( dexamethasone) |
Multiple anti-inflammatory targets |
Rhinitis |
|
House dust mite chronic model |
Mouse |
IL-5 antibodies, prednisolone, PDE4 (roflumilast) inhaled steroids (budesonide) |
Multiple anti-inflammatory targets |
Asthma |
Assessment of the time course of chronic inflammation in the Murine house dust mite model |
IL-13 PK/PD goblet cell hyperplasia model |
Rat |
- |
IL-13 pathways for mucolytics |
Cystic fibrosis |
|
LPS neutrophil chemotaxis PK/PD model ( inhaled and systemic) |
Rat, mouse, guinea pig |
Steroids, PDE4 antagonists, P38 MAP Kinases |
Neutrophil chemotaxis |
COPD, neutrophilic asthma |
Acute markers of neutrophilic lung infiltration in the nonhuman primate LPS model |
Inhaled LPS + FMLP PK/PD model |
Rat |
AZD9668,Sivelestat (NE inhibitors) |
Neutrophil elastase |
COPD |
|
Acute 5, 12 and 17 day Tobacco smoke model (steroid insensitive) |
Mouse |
PDE4 (Roflumilast), inhaled PDE4 (GSK256066) |
Multiple anti-inflammatory |
COPD |
Efficacy of an inhaled PDE4 inhibitor, GSK256066, delivered by a novel dry powder preclinical inhalation delivery system in the acute cigarette smoke induced pulmonary inflammation model |
Human neutrophil elastase lung haemorrhage model |
Rat |
AZD9668, Sivelestat (NE inhibitors) |
Neutrophil elastase |
COPD, bronchiectasis |
|
Anti-tussive model |
Guinea pig |
codeine |
Anti-tussives |
Chronic Cough/ COPD, lung fibrosis) |
|
Bronchoconstriction models |
Guinea pig |
Beta agonists (LABA) (e.g. Formoterol), Long acting muscarinic agonists (LAMA) e.g. tiotropium and dual pharmacophores muscarinic antagonists/beta agonist (MABA) e.g Batefenterol |
Bronchodilators (LABA, LAMA & MABA) |
COPD (asthma) |
|
Bleomycin induced lung fibrosis model |
Rat , mouse |
Pirfenidone, Nintedanib |
Multiple targets for lung fibrosis |
Pulmonary Fibrosis (IPF) |
Changes in airway platelet population and morphology in a Murine model of lung fibrosis; Correlation of Nintedanib efficacy on fibrotic lesion deposition and lung function within a rat IPF model;
Nintedanib attenuates lung function decline in a Bleomycin-induced rat model of pulmonary fibrosis;
Repeat low doses of Bleomycin induces progressive changes in Murine lung mechanics associated with the development of pulmonary fibrosis;
|
Chlorine induced lung injury |
Rat |
N/A ( Orphan drug indication) |
Chemical lung injury |
Chemical exposure |
|
H1N1 viral pulmonary inflammation model |
Mouse/Ferret |
Anti-infectives (Oseltamivir “Tamiflu”) |
Anti-infectives or viral induce lung injury |
Infectious disease/lung injury/COPD exacerbations |
Assessment of viral load and time course of pulmonary inflammation in a Murine model of H1N1 (PR8) influenza virus infection |
Pseudomonas aeruginosa lung injury and lung infection model |
Mouse |
Anti-infectives antibiotics/anti-inflammatory/mucolytics |
Anti-infectives or bacteria induce lung injury |
Infectious disease/Cystic Fibrosis/COPD exacerbations |
|
Allergic Aspergillus |
Mouse |
Anti-infectives (anti-fungal) |
Anti-fungals or allergy induce lung injury |
Allergic Aspergillosis |
|